GEROPHARM is the winner of the "Business Gazelle 2016" in the sphere of pharmaceutical industry and import substitution
The 13th annual award "Business Gazelle 2016" was held on June 2 in the Konyushenny wing of Yusupov Palace. GEROPHARM Group was marked as the most powerful gazelle in the field of pharmaceutical industry and import substitution.
"Business Gazelle" is an annual rating of the "Delovoy Peterburg" newspaper which includes the list of the fast-growing companies of St. Petersburg, operating over three years and showing stable turnover increase.
Having started the production of genetically engineered human insulins in the middle of 2014, within just a year and a half GEROPHARM Group has managed to establish a stable production of these socially significant drugs and achieve real success in the field of import substitution. By the end of 2015, the market share of genetically engineered insulins, manufactured by GEROPHARM-Bio, has increased from 1% to 10%.
The company is currently expanding its pipeline of antidiabetic drug products. It is developing a new generation of analogue insulins. The development is carried out in accordance with the international standards, which result in high export potential of the project. GEROPHARM is planning to introduce these drugs to the market in 2019. At the moment the company is carrying out a large-scale investment project in the Pushkin district of St. Petersburg on the creation of drug production platform on the basis of a full cycle principle for the treatment of socially significant diseases.